Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Positive preclinical data for Advaxis cancer drug
The research indicates that listeria activates the body’s cytotoxic T cells to boost the immune system’s capability to fight cancer cells. Lovaxin C is intended as a treatment
The research indicates that listeria activates the body’s cytotoxic T cells to boost the immune system’s capability to fight cancer cells. Lovaxin C is intended as a treatment
Cethrin has demonstrated neuro-protective and neuro-regenerative properties in vitro as well as in vivo studies suggesting its potential as an effective treatment for acute spinal cord injury. Acute
Results from the study, the largest clinical trial to date for newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, showed that
The follow-up data was taken after nearly six years and demonstrated that the disease did not progress in the patients for an average of 37.7 months after the
The trials will include a comparison of Hana’s nasal spray with GlaxoSmithKline’s Zofran which delivers the same active ingredient in the form of a tablet. A nasal spray
MedImmune’s nasal spray CAIV-T produced a reduction of 55% in influenza illness caused by any influenza strain compared to a standard injectable flu vaccine. 8.6% of the participants
The trial is expected to enroll approximately 370 patients who have not had prior treatment for non small cell lung cancer and who will be randomized into either
OvaRex is an immunotherapeutic monoclonal antibody being developed for the treatment of stage III/IV advanced ovarian cancer following successful completion of front-line therapy. The antibody targets CA125, a
In January 2005, Ambit and Bristol-Myers Squibb entered into a drug screening collaboration in which Bristol-Myers Squibb used Ambit’s KinomeScan platform to characterize the specificity of certain Bristol-Myers
The data demonstrates that the time to disease progression with Revlimid plus dexamethasone was 49 weeks, compared with 20 weeks for placebo plus dexamethasone. The best response rate